Stock MYMD MYMD PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases MyMD Pharmaceuticals, Inc.

Equities

MYMD

US62856X2018

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
2.84 USD +1.07% Intraday chart for MyMD Pharmaceuticals, Inc. +13.60% -63.41%
Apr. 18 MyMD Pharmaceuticals, Inc. Announces Resignation of Adam Kaplin as Chief Scientific Officer CI
Apr. 09 Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ladenburg Thalmann, Esteemed Wall Street Long-Standing Stalwart Since 1876, Advocates 'Buy' for Intelligent Bio, Precision Bio, and More: VTAK, INBS, LASE, MYMD, RVSN
AQ
MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
BU
MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
BU
MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis
BU
Developing a first-in-class small molecule drug for inflammatory disease
AQ
MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD, Reduced Acute Inflammatory Pain
AQ
MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain
BU
MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF- Market Disrupter, at BioFuture 2023
AQ
MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023
BU
FDA Accepts MyMD Pharmaceuticals Investigational New Drug Application for Phase 2 Study of oral TNF- inhibitor MYMD-1 in Rheumatoid Arthritis
AQ
FDA Accepts MyMD Pharmaceuticals’ Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1® in Rheumatoid Arthritis (RA)
BU
MyMD Pharmaceuticals : Joshua Silverman - Chairman, MyMD Pharmaceuticals, Inc. Chris Chapman - President, Director, and Chief Medical Officer, MyMD Pharmaceuticals, Inc. Adam Kaplin - Chief Scientific Officer, MyMD Pharmaceuticals, Inc - Form 8-K
PU
Top Under-the-Radar Small Cap Stocks to Watch Now! STPGF / STGO.T, WKHS, MYMD, KAVL, HNRC
AQ
MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial Results
BU
MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF- Inhibitor MYMD-1 in Sarcopenia, Age-Related Frailty
AQ
MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty
BU
MyMD Pharmaceuticals : Shareholder Director Nominations - Form 8-K
PU
MyMD Pharmaceuticals Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan
AQ
MYMD PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
MyMD Pharmaceuticals : Company Overview
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MYMD Stock
  4. News MyMD Pharmaceuticals, Inc.
  5. Press Releases